Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.
OBJECTIVE
HIV/hepatitis C virus (HCV) coinfection causes accelerated liver disease compared to HCV monoinfection, and only 30-60% of HIV/HCV-coinfected individuals respond to HCV therapy with pegylated interferon and ribavirin. There are currently no biomarkers that predict treatment response in these coinfected patients.


METHODS
We investigated whether there is an association between HCV treatment response and SNPs of apoptosis-related genes during HIV/HCV coinfection.


METHODS
Genomic DNA from 53 HIV/HCV-coinfected individuals was analyzed for 82 SNPs of 10 apoptosis-related genes.


RESULTS
We found that the presence of the rs4242392 SNP in tumor necrosis factor receptor superfamily, member 10a (TNFRSF10A), which encodes for tumor necrosis factor-related apoptosis-inducing ligand receptor 1, predicts poor outcome to HCV therapy, in HIV/HCV-co-infected patients [odds ratio 5.91 (95% confidence interval 1.63-21.38, P = 0.007)].


CONCLUSIONS
The rs4242392 SNP of the tumor necrosis factor-related apoptosis-inducing ligand receptor 1 gene predicted poor interferon-based HCV treatment response in HIV/HCV-coinfected patients.
Rizza
Stacey A
SA
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Cummins
Nathan W
NW
Rider
David N
DN
Saeed
Sahar
S
Klein
Marina B
MB
Badley
Andrew D
AD
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002170:Canada; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008107:Liver Diseases / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012367:RNA, Viral; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000235:genetics*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D053219:Receptors, Tumor Necrosis Factor, Member 25; D011994:Recombinant Proteins; D012254:Ribavirin
J Hepatol. 2008 Oct;49(4):548-56
18619701
Cell Death Differ. 2001 Feb;8(2):113-26
11313713
J Neuroimmunol. 2005 Oct;167(1-2):170-4
16040132
Lancet. 2001 Sep 22;358(9286):958-65
11583749
Medicina (Kaunas). 2008;44(7):510-20
18695347
Int J Epidemiol. 2010 Oct;39(5):1162-9
19786463
J Viral Hepat. 2007 Jul;14(7):468-77
17576388
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):2002-5
17035413
Gastroenterology. 2010 May;138(5):1885-97
20334827
Blood. 2005 Nov 15;106(10):3524-31
16046522
J Viral Hepat. 2010 Apr;17(4):245-53
19709361
Blood. 1994 Aug 15;84(4):1020-3
8049420
AIDS. 2007 May 31;21(9):1073-89
17502718
Curr Mol Med. 2009 May;9(4):495-505
19519406
Gut. 2005 Nov;54(11):1590-6
16227360
N Engl J Med. 2004 Jul 29;351(5):438-50
15282351
Cancer Biomark. 2007;3(2):89-93
17522430
Clin Cancer Res. 2000 Feb;6(2):335-46
10690508
Clin Infect Dis. 2001 Aug 15;33(4):562-9
11462196
J Neuroimmunol. 2004 Apr;149(1-2):195-201
15020080
Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15903-8
19717445
J Transl Med. 2008 Aug 09;6:44
18691426
AIDS. 2003 May 2;17(7):1023-8
12700452
J Virol. 2001 Nov;75(22):11128-36
11602752
J Infect Dis. 2006 Apr 1;193(7):945-53
16518756
J Infect Dis. 2006 Oct 15;194(8):1098-107
16991084
Nat Genet. 2009 Oct;41(10):1105-9
19749757